NRF2 Dysregulation and Therapeutic Insights Across Chronic Kidney Diseases

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Chronic kidney disease (CKD) presents a significant global health challenge with limited treatments targeting its core mechanisms.
• Nuclear factor erythroid 2-related factor 2 (NRF2) is a critical regulator of cellular responses to oxidative stress and inflammation, making it a promising therapeutic target for CKD.
• Despite preclinical promise, no NRF2-targeting drugs have gained clinical approval for CKD.

Purpose of the Study:

• To review and synthesize current evidence on the heterogeneity of NRF2 activity in various CKD subtypes.
• To explore the therapeutic implications of NRF2 modulation across different CKD etiologies and stages.
• To highlight the importance of context-specific NRF2 targeting for effective CKD treatment and drug development.

Main Methods:

• Literature review and synthesis of preclinical and clinical data on NRF2 in CKD.
• Analysis of NRF2 activity variations based on CKD etiology, stage, and progression rate.
• Evaluation of the consequences of both NRF2 overactivation and indiscriminate activation in different CKD contexts.

Main Results:

• NRF2 activity exhibits significant heterogeneity across CKD subtypes, influenced by disease cause, stage, and progression.
• The efficacy of NRF2 activation as a therapeutic strategy is highly dependent on precise modulation tailored to the specific disease context.
• Indiscriminate NRF2 activation can have divergent effects depending on the CKD etiology and cellular environment.

Conclusions:

• A nuanced, context-specific approach is essential for developing effective NRF2-targeted therapies for CKD.
• Understanding the heterogeneity of NRF2 activity is key to guiding future drug development strategies in nephrology.
• Future research should focus on precise modulation of NRF2 pathways tailored to individual CKD patient profiles and disease characteristics.